Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.47 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12369341 | 0.83 | RXRA (0.41) | MTNR1AMTNR1BACHECA2ALDH1A1 | |
| SCHEMBL26042904 | 0.82 | TAAR1 (0.51) | SLC6A2SLC6A4MTNR1AMTNR1BTAAR1 | |
| SCHEMBL14940633 | 0.82 | TAAR1 (0.48) | MTNR1AMTNR1BTAAR1HSD17B2ALOX15 | |
| SCHEMBL24300289 | 0.80 | TP53 (0.49) | MTNR1AMTNR1BALOX15ALDH1A1CYP3A4 | |
| SCHEMBL1134082 | 0.79 | MTNR1A (0.61) | MTNR1AMTNR1BHSD17B2ALOX15HSD17B1 | |
| SCHEMBL29636366 | 0.79 | ACHE (0.52) | MTNR1AMTNR1BHSD17B2ALOX15HSD17B1 | |
| SCHEMBL30054343 | 0.79 | MTNR1A (0.61) | MTNR1AMTNR1BHSD17B2ALOX15HSD17B1 | |
| SCHEMBL820669 | 0.79 | ACHE (0.52) | MTNR1AMTNR1BHSD17B2ALOX15HSD17B1 | |
| SCHEMBL19009081 | 0.79 | ALDH1A1 (0.50) | ALDH1A1CYP3A4 | |
| SCHEMBL24300188 | 0.79 | GRM2 (0.45) | MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102285904-B | Method for preparing rivastigmine | CHENGDU INST BIOLOGY CAS | 2013-06-05 | — | — | CN | claimed |
| CN-102285904-A | Method for preparing rivastigmine | — | 2011-12-21 | — | — | CN | claimed |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| US-10889556-B2 | Compositions and methods for inhibiting influenza RNA polymerase PA endonuclease | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-01-12 | — | — | US | disclosed |
| US-20190106398-A1 | COMPOSITIONS AND METHODS FOR INHIBITING INFLUENZA RNA POLYMERASE PA ENDONUCLEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-04-11 | — | — | US | disclosed |
| CN-108822000-A | A kind of method of reduction amination synthesis (S)-Rivastigmine | 山东师范大学 | 2018-11-16 | — | — | CN | disclosed |
| US-20170174639-A1 | EIS INHIBITORS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2017-06-22 | — | — | US | disclosed |
| CN-102285904-B | Method for preparing rivastigmine | CHENGDU INST BIOLOGY CAS | 2013-06-05 | — | — | CN | disclosed |
| CN-102285904-A | Method for preparing rivastigmine | — | 2011-12-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190106398-A1 | COMPOSITIONS AND METHODS FOR INHIBITING INFLUENZA RNA POLYMERASE PA ENDONUCLEASE | POLRMT, RNASE1, POLM | SLC6A2 4258/4885SLC6A4 4358/4885MTNR1A 2103/4885 |
| US-20170174639-A1 | EIS INHIBITORS | ABCC1, ATP5ME, ABCG2 | SLC6A2 1634/4885SLC6A4 3058/4885MTNR1A 4222/4885 |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | SLC6A2 2569/4885SLC6A4 2521/4885MTNR1A 2382/4885 |
| US-10889556-B2 | Compositions and methods for inhibiting influenza RNA polymerase PA endonuclease | POLRMT, RNASE1, POLM | SLC6A2 4258/4885SLC6A4 4358/4885MTNR1A 2103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.